TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06628102

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chest CT Scan
Description: Chest CT Scan
Study: NCT06732674

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: A home monitoring strategy with event driven management
Description: Bi-weekly home monitoring with forced vital capacity (FVC), patient reported outcome measures (PROMs), at-home measures of blood oxygen levels (SpO2) during 1-minute-sit-to-stand test (1MSTS) and temperature with algorithm based risk evaluation of deterioration and infection and consecutive event driven management
Study: NCT05705219

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D-MPUS
Description: Participants will receive approximately \< 20 minutes ultrasound scan to locate the lesion followed by acquisition of 3D-MPUS acquisition.
Study: NCT05041855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Healthy Living Program/La Vida Saludable
Description: A whole-family group childhood obesity intervention delivered at community recreation centers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recommended Treatment of Obesity in Primary Care
Description: A healthy lifestyle counseling protocol that enhances usual primary care
Study: NCT05221229

Intervention type: DRUG
Intervention: Liraglutide plus upstream risk factors modification advice and consultation
Description: Patients will be on treatment with daily injections of Liraglutide for a total of 65 weeks. During initial consultation for AF ablation, patients' BMI, risk factors status and baseline blood tests were performed and reviewed. Then the patients were discussed and encouraged to achieve optimal goal of risk factors modifications by non pharmacological and pharmacological measures.
Study: NCT06570655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A injection
Description: intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A injection
Description: intravenous bolus
Study: NCT05415501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sentence training
Description: Participants will be trained to read, make, and recall sentences during each session.
Study: NCT04713449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Empowered Survivor Online
Description: Informational online intervention for head and neck cancer survivors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Springboard Beyond Cancer
Description: Informational online intervention for all cancer survivors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Survey measures administered at BL, two and 6 months post-baseline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Survey measures administered at BL, two and 6 months post-baseline
Study: NCT03998605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abuse Prevention Program
Description: The abuse prevention program will be comprised of nine shared learning modules for the individual with Intellectual Disabilities (ID) and a care provider. Each shared module will contain an action step in the Individual Response Plan and will include video, guided practice and workbook activities to equip persons with ID with a range of judgment, decision-making skills and the efficacy needed for identifying, rejecting, and reporting abuse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: The control group will receive worksheets from the ESCAPE-NOW curriculum.
Study: NCT06234358

Intervention type: DEVICE
Intervention: osteosynthesis
Description: calcaneus osteosynthesis is a surgical fixation of a displaced fracture of the calcaneous bone. The surgery is performed under general or regional anesthesia. A scar is made on the lateral side of the ankle below the lateral malleolus. The bone fragments are repositioned as anatomically as possible. They are fixed by a percutaneous nailing fastener.
Study: NCT04760704

Intervention type: BIOLOGICAL
Intervention: Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration
Description: Specific T cells and specific antibodies assessment

Intervention type: BIOLOGICAL
Intervention: Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration
Description: Specific T cells and specific antibodies assessment
Study: NCT05045040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-based empathetic communication support program to promote ACP discussion
Description: Patients in the intervention group are provided a mobile-based empathic communication support program-an app on a mobile phone. The app comprises a QPL (46 questions in eight categories) and questions about the patient's preferred treatment and end-of-life care based on their values and goals. Then, they proceed with the content themselves, at home or anywhere, at any time. Between app registration and the next outpatient visit, the patient is interviewed (by phone or in person) by a nurse or a clinical psychologist, who helps them prepare for the discussion with the physician and asks questions based on the patient's app responses for 30 minutes to an hour. During the outpatient visit, feedback is provided to patients and their physicians based on the interview. The duration between the start of app use and the next consultation is a minimum of one week and a maximum of four weeks.
Study: NCT04990739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTB-9655
Description: MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.~Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime.
Study: NCT05694598

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VGR-R01
Description: CYP4v2-coding gene delivered by AAV vector
Study: NCT05772364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loading of low-calcium water first, then high-calcium water
Description: All cohort subjects are asked to consume water with less than 5 mg/L of calcium first, then are asked to consume water with at least 400 mg/L of calcium
Study: NCT05289674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Calorie Formula
Description: The high calorie formula is given as much as 300 kcal/day for 90 days after the subject were diagnosed with tuberculosis (TB) or urinary tract infection (UTI), determine as day 1. the diagnosis were determined by pediatrician. Before the intervention (day 0) and after the intervention (day 61), the subjects were taken the blood by laboratory employee of the private hospital in Surabaya, Indonesia
Study: NCT06407206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub occipital muscle inhibition technique and conventional therapy
Description: Patient is in supine position Therapist sits near the head of the participant and places his hand below the head of the participant With the pads of hand therapist palpates the arch of atlas between the occipital protuberance and spinous process of axis and place the middle and ring finger over it by flexing the metacarpophalangeal joint in 90 degrees of flexion, base of skull will rest on hands Pressure is exerted in upward direction towards the therapist and is maintained for two minutes so that the muscle scan relax Participants are guided to keep their eyes close in order to avoid movement which affects the tone of sub occipital muscle

Intervention type: OTHER
Group type: OTHER
Intervention: conventional therapy
Description: Transcutaneous electrical nerve stimulation at lower back and hamstring muscles (pulse rate: 4Hertz, pulse duration: 150µs for 15mins) Hot pack ( 15mins),Ankle pumps (15 reps with 5 sec hold), Knee Range of motions (flexion and extension,10 reps),Quadriceps set (10 reps,5 sec hold),Vastus Medialis oblique (10 reps 5 sec hold),Gluteus sets (10 reps, 5 sec hold),Single knee to chest (10 reps with 10 sec hold) McKenzie exercises (10 reps with 10 sec hold and 10 sec rest),Stretching of calf and hamstring muscles (passive stretching,7 reps with 5 sec hold).
Study: NCT05177991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: 20cc of Liposomal Bupivacaine for TAP block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20cc of Bupivacaine for TAP block
Study: NCT05462093

Intervention type: DEVICE
Group type: OTHER
Intervention: Liver Multiscan sequences
Description: Additional Liver Multiscan sequences will be performed after the MRI liver with MRCP is performed, taking approximately 15 minutes.

Intervention type: DEVICE
Group type: OTHER
Intervention: Liver Multiscan analysis
Description: Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRCP+
Description: Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
Study: NCT06656169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous polyvidone collagen
Description: Use collagen-polyvidone at a dose of 0.2 ml, applied to the affected area of the hand.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: administer saline solution at a dose of 0.2 ml, applied to the affected area of the hand.
Study: NCT06656429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transforaminal Epidural Steroid Injections
Description: Transforaminal Epidural Steroid Injections
Study: NCT06019988

Intervention type: OTHER
Group type: OTHER
Intervention: Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening
Description: All patients who participate in the trial will receive one of three social and behavioral determinants of health (SBDOH) screening instruments (AHC-HRSN, Health Leads, or NCCN DT + PL). Any patients who do not complete the screening within 48 hours of its administration will be randomized to receive the same screening via one of two modality arms (Chatbot or IVR System)

Intervention type: OTHER
Group type: OTHER
Intervention: Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening
Description: All patients who participate in the trial will receive one of three social and behavioral determinants of health (SBDOH) screening instruments (AHC-HRSN, Health Leads, or NCCN DT + PL). Any patients who do not complete the screening within 48 hours of its administration will be randomized to receive the same screening via one of two modality arms (Chatbot or IVR System)

Intervention type: OTHER
Group type: OTHER
Intervention: Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening
Description: All patients who participate in the trial will receive one of three social and behavioral determinants of health (SBDOH) screening instruments (AHC-HRSN, Health Leads, or NCCN DT + PL). Any patients who do not complete the screening within 48 hours of its administration will be randomized to receive the same screening via one of two modality arms (Chatbot or IVR System)

Intervention type: OTHER
Group type: OTHER
Intervention: Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening
Description: All patients who participate in the trial will receive one of three social and behavioral determinants of health (SBDOH) screening instruments (AHC-HRSN, Health Leads, or NCCN DT + PL). Any patients who do not complete the screening within 48 hours of its administration will be randomized to receive the same screening via one of two modality arms (Chatbot or IVR System)

Intervention type: OTHER
Group type: OTHER
Intervention: Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening
Description: All patients who participate in the trial will receive one of three social and behavioral determinants of health (SBDOH) screening instruments (AHC-HRSN, Health Leads, or NCCN DT + PL). Any patients who do not complete the screening within 48 hours of its administration will be randomized to receive the same screening via one of two modality arms (Chatbot or IVR System)
Study: NCT05174624

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04245163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational program
Description: The intervention program will include 3 phases. At phase 1 a presentation on Microsoft PowerPoint in order to increase the general knowledge about glaucoma. At phase 2 a video and a one on one teaching to develop skills of administering the eye drops in a correct and systematic way. At phase 3, a discussion in order to identify cues to action that can easily be adopted by the patient in his/her daily routine, (such as, how to remember to put in drops) will take place.
Study: NCT05735054

Intervention type: PROCEDURE
Intervention: endoscopic thyroidectomy
Description: the patients who underwent endoscopic transaxillary thyroidectomy
Study: NCT06293144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
Study: NCT05779644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide is injected once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide is injected once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is taken orally daily.
Study: NCT04691232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regulatory T cells
Description: Autologous, ex vivo expanded, regulatory T cells
Study: NCT06188546

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis
Study: NCT06390215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School Readiness Coaching Intervention
Description: Two 1-hr School Readiness Coaching Session
Study: NCT06621407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24 hours active subperiostal drainage
Description: 24 hours active subperiostal drainage after single burr hole evacuation of a chronic subdural hematoma
Study: NCT05122715

Intervention type: DEVICE
Group type: OTHER
Intervention: Additional PET/CT Scan
Description: The subject will undergo two PET/CT scans, one on the DMI scanner and one on the OMNI scanner.

Intervention type: DEVICE
Group type: OTHER
Intervention: Additional PET/CT Scan
Description: The subject will undergo two PET/CT scans, one on the DMI scanner and one on the OMNI scanner.
Study: NCT06413329

Intervention type: BEHAVIORAL
Intervention: preoperative physical activity level within 3 months
Description: The exercise compliance criteria are moderate exercise of at least 150 minutes per week or high-intensity exercise of at least 75 minutes per week.
Study: NCT06621407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24 hours passive subdural drainage
Description: 24 hours passive subdural drainage after single burr hole evacuation of a chronic subdural hematoma
Study: NCT06618157

Intervention type: DEVICE
Group type: OTHER
Intervention: Cerebellothalamic optimized deep brain stimulation
Description: A deep brain stimulation plan will be created by maximizing the cerebellothalamic pathway on the patient-specific connectomic deep brain stimulation model

Intervention type: DEVICE
Group type: OTHER
Intervention: Cerebellothalamic optimized deep brain stimulation
Description: A deep brain stimulation plan will be created by maximizing the cerebellothalamic pathway on the patient-specific connectomic deep brain stimulation model

Intervention type: DEVICE
Group type: OTHER
Intervention: Pallidothalamic optimized deep brain stimulation
Description: A deep brain stimulation plan will be created by maximizing the Pallidothalamic pathway on the patient-specific connectomic deep brain stimulation model
Study: NCT04994236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)
Description: The FOLFOX regiments were given via hepatic artery catheterization, including oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2, followed by fluorouracil infusion 2400 mg/m2 for 46 hours. If no severe adverse events occurred, the treatment will be repeated every 3 weeks.
Study: NCT06618157

Intervention type: DEVICE
Group type: OTHER
Intervention: Pallidothalamic optimized deep brain stimulation
Description: A deep brain stimulation plan will be created by maximizing the Pallidothalamic pathway on the patient-specific connectomic deep brain stimulation model

Intervention type: OTHER
Group type: OTHER
Intervention: No deep brain stimulation
Description: Patients will also be tested without any deep brain stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: No deep brain stimulation
Description: Patients will also be tested without any deep brain stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Usual care deep brain stimulation
Description: Patient will also be tested with the deep brain stimulation clinical settings that were previously established during usual care with their neurologist

Intervention type: DEVICE
Group type: OTHER
Intervention: Usual care deep brain stimulation
Description: Patient will also be tested with the deep brain stimulation clinical settings that were previously established during usual care with their neurologist
Study: NCT05850507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant novel coronavirus protein vaccine (CHO cells)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells) .
Study: NCT06061419

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Huel Powder
Description: Huel Powder v3.0 white, vanilla flavour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Huel Powder
Description: Huel Powder v3.0 white, vanilla flavour
Study: NCT05575310

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Articular knee surface replacement

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Articular knee surface replacement
Study: NCT06321575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)
Description: Golazo® Peripheral AS is a sterile, single-use percutaneous device that has two main components: 1) the Golazo® Accustrike atherectomy catheter, and 2) the Golazo® motorized drive unit (MDU) and is intended for use in atherectomy of the peripheral vasculature.
Study: NCT05812716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resiLIR Healthcare Professionals
Description: Weeks 1 and 2: Theoretical part on stress, resilience, self-care, and self-compassion~Weeks 3 to 6: Training phase of a weekly introduced practical exercise (reflection on living with ease, self-compassionate body scan, planning of positive activities, self-compassionate letter). This phase additionally includes smartphone reminders to apply the exercises in everyday life.
Study: NCT06521489

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Asymmetrical High Flow Nasal Cannula Oxygenation
Description: Asymmetrical High Flow Nasal Cannula Oxygenation will be implemented in this study group. (1st study group, 60l/min airflow, 60% fiO2)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional High Flow Nasal Cannula Oxygenation
Description: Conventional High Flow Nasal Cannula Oxygenation will be implemented in this study group. (2nd study group, 60l/min airflow, 60% fiO2)
Study: NCT06084806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-ARAG PET
Description: Two imaging sessions
Study: NCT05035420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Performance of the NIRS biosensor will be explored in comparison to this commercial wearable.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Douglas Bag
Description: The Douglas Bag will be used for inducing hypercapnia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Periflux 6000 EPOS
Description: Tissue oxygen saturation measured by the Periflux 6000 will be compared with peripheral tissue saturation measured with the NIRS biosensor both at rest and during the induced hypercapnia, paced breathing and breath holding.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOPAC
Description: The BIOPAC system will be used to record the PPG signal, cardiovascular hemodynamics, and respiratory parameters in order to noninvasively monitor the heart rate, heart rate variability, respiratory rate, respiratory effort index, and arterial oxygen saturation.
Study: NCT06740370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
Study: NCT06186128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Universal Basic Income
Description: Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
Study: NCT06498713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 650 mg Oral Tablet
Description: 650 mg pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650mg Liquid
Description: 650 mg liquid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD pump
Description: Primed and programmed to delivery 650 mg liquid acetaminophen into a medication cup every 4 hours as needed.